M.D., University of Minnesota, Medicine, 1984.
B.A., Saint Olaf College, 1979.
Hematopoietic cell transplant (HCT) is the only curative therapy for many life-threatening hematologic diseases, and theoretically could cure other chronic hematologic and immunologic disorders. The research projects under Dr. Woolfrey’s direction are aimed toward improving the effectiveness of hematopoietic cell transplants, particularly for patients with nonmalignant disorders. These studies explore the use of lower dose (nonmyeloablative) conditioning regimens to reduce the short and long term toxicities associated with HCT, the use of HCT to restore normal immunity in patients with HIV or refractory autoimmune diseases, and the use of alternative donors, including unrelated and mismatched related donors.
1. Nonmyeloablative conditioning regimen using low-dose total body irradiation with or without fludarabine for treatment of immune deficiencies, metabolic storage diseases, hemaglobinopathies, and other inherited disorders. The primary goal of each study is to determine whether establishment of stable mixed chimerism using a low-toxicity regimen results in amelioration of the disease, as an alternative to standard transplant procedures.
2. Nonmyeloablative conditioning regimen using low-dose total body irradiation and fludarabine for treatment of HIV. The primary goal is to determine whether immunity can be reconstituted in HIV patients using a non-toxic regimen for HCT. A second goal is to establish a method for allogeneic transplant that is tolerated by patients with HIV for cure of life-threatening malignancies.
3. High-dose immunoablative therapy followed by autologous HCT for treatment of refractory autoimmune disorders. The primary goal is to determine whether immune ablation followed by rescue with purified autologous stem cells could result in restoration of immunity without recurrence of the autoreactive T cells. Patients eligible include children with juvenile rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, or dermatomyositis.
4. Use of haploidentical donors for HCT in the treatment of life-threatening hematologic diseases in children. The goal of these studies has been to determine the outcome of transplants for patients who undergo HCT using haploidentical donors.
Bone Marrrow Transplantation
Hematopoietic Cell Transplantation
Juvenile Rheumatoid Arthritis
(Reading, Writing, Speaking)
English: (Fluent, Fluent, Fluent)
American Society for Blood and Marrow Transplantation
American Society of Hematology
Society for Leukocyte Biology
Society for Pediatric Research
Honors and Awards
1994, American Cancer Society Young Investigator Honored Presentation, American Cancer Society
1984, Minnesota Medical Foundation Undergraduate Research Award,
1978, Honors Program, Cambridge University, Cambridge, England
2003, Associate Professor, University of Washington, School of Medicine, Pediatrics
2002, Associate Member, Fred Hutchinson Cancer Research Center, Pediatric Bone Marrow Transplantation and Immunogenetics, Clinical Research Division
2000-2003, Assistant Professor, University of Washington, School of Medicine, Pediatrics
1996-2002, Assistant Member, Fred Hutchinson Cancer Research Center, Pediatric Bone Marrow Transplantation and Immunogenetics
1996-2002, Acting Assistant Professor, University of Washington, School of Medicine, Pediatrics
1995-1995, Director, Yale University, School of Medicine, Pediatrics, Pediatric Stem Cell Program
1995-1995, Instructor, Yale University, School of Medicine, Pediatrics
1994-1994, Associate in Clinical Research, Fred Hutchinson Cancer Research Center, Clinical Transplantation Support, Clinical Research Division
1992-1995, Senior Research Fellow, Fred Hutchinson Cancer Research Center and Virginia Mason Research Center
Severe combined immunodeficiency (SCID) presenting with neonatal aplastic anemia.. Pediatric blood & cancer.. 2015.
Outcome of pediatric hematopoietic stem cell transplant recipients requiring mechanical ventilation.. Journal of intensive care medicine. 29(1):31-7.. 2014.
Challenges and Potential Solutions for Recruitment and Retention of Hematopoietic Cell Transplant Physicians: the National Marrow Donor Program's System Capacity Initiative Physician Workforce Group Report.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2014.
Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia.. Leukemia research and treatment. 2014:421723.. 2014.
Robust suppression of env-SHIV viremia in Macaca nemestrina by 3-drug ART is independent of timing of initiation during chronic infection.. Journal of medical primatology. 42(5):237-46.. 2013.
Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(12):1530-8.. 2013.
Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2012.
Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis.. Bone marrow transplantation. 47(6):810-816.. 2012.
Success of allogeneic marrow transplantation for children with severe aplastic anaemia.. British journal of haematology. 158(1):120-8.. 2012.
Analysis of risk factors influencing outcome in children with myelodysplastic syndrome after unrelated cord blood transplantation.. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 25(3):449-54.. 2011.
Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 17(3):341-50.. 2011.
HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 17(6):885-92.. 2011.
Outcome of myeloablative conditioning and unrelated donor hematopoietic cell transplantation for childhood acute lymphoblastic leukemia in third remission.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 17(12):1833-40.. 2011.
Treatment of Fanconi anemia patients using fludarabine and low-dose TBI, followed by unrelated donor hematopoietic cell transplantation.. Bone marrow transplantation. 46(4):539-44.. 2011.
HLA-allele matched unrelated donors compared to HLA-matched sibling donors: role of cell source and disease risk category.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(10):1382-7.. 2010.
Stable hematopoietic cell engraftment after low-intensity nonmyeloablative conditioning in patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome.. The Journal of allergy and clinical immunology. 126(5):1000-5.. 2010.